Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Xanthus Pharmaceuticals has begun patient dosing in a Phase III trial of its drug Xanafide. Patients with secondary acute myeloid leukemia are poorly served by existing drug therapy; physicians are therefore likely to be enthusiastic about a drug which can improve treatment outcomes. At this stage of development, however, it is too early to forecast the chances of Xanthus's drug being successful.
Published By Datamonitor
|
10 Oct 2007 |
|
CommentWire
|
The termination of Pristiq for fibromyalgia represents another setback for Wyeth, which had high hopes for its follow-on drug to Effexor. However, all is not lost as Wyeth's greatest commercial opportunity for Pristiq will be gained through indications for depression and menopausal symptoms, although heart and liver safety concerns added to regulatory delays may still limit the drug's potential.
Published By Datamonitor
|
10 Aug 2007 |
|
CommentWire
|
The 2002 halt of the WHI study using Wyeth's [WYE] Prempro triggered heavy losses to Premarin family sales. Now the remaining study, including Premarin itself, has also come to an abrupt end due an increased risk of stroke. After losing around $1 billion of the brand's annual revenue since 2002, this slide is now unlikely to slow.
Published By Datamonitor
|
05 Mar 2004 |
|
CommentWire
|
A recent study published in the Journal of the American Medical Association has shown that Wyeth's hormone combination therapy Prempro increases the risk of probable dementia in postmenopausal women aged 65 years or older. Further studies are needed to establish the role of estrogen therapies in the onset of Alzheimer's disease.
Published By Datamonitor
|
29 May 2003 |
|
CommentWire
|
Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.
Published By Datamonitor
|
29 Jul 2009 |
|
CommentWire
|
Wyeth has received an approvable letter from the FDA which confirms that bazedoxifene, to be marketed as Viviant, is likely to be indicated for the prevention of postmenopausal osteoporosis. This is the first step in what Datamonitor expects to be a successful and maintained brand lifecycle management strategy.
Published By Datamonitor
|
25 Apr 2007 |
|
CommentWire
|
The expanding versatility of Wyeth's blockbuster Effexor is key to its continued success. Sales should top $2 billion in 2003. However, competition is strong with large players including Pfizer and GlaxoSmithKline battling for a share of the lucrative mood disorders market. Nevertheless, Effexor's advantageous mechanism of action and convenient once-daily dosage will provide the edge over rivals.
Published By Datamonitor
|
13 Feb 2003 |
|
CommentWire
|
Wyeth's [WYE] pipeline is looking bare, particularly in women's health, with only two linked candidates in trials for osteoporosis/menopause. Recent agreements with biotech firms Tanox [TNOX] and Galapagos Genomics show the company is finally following other osteoporosis players' examples in a bid to remain in this lucrative market.
Published By Datamonitor
|
21 Nov 2003 |
|
CommentWire
|
Wyeth has released the findings of the study, which pooled together results of eight double-blind studies and compared Effexor XR to a leading serotonin selective re-uptake inhibitor. Although the drug's sales should be high it could suffer at the hands of strong competition from Lilly's duloxetine.<BR />
Published By Datamonitor
|
13 Dec 2002 |
|
CommentWire
|
Wyeth [WYE] has warned that its antidepressant Effexor (venlafaxine) is not effective for treating depression in children and teenagers, raising further concerns over the safety of prescribing antidepressants to children. However, due to the drug's ongoing success and growth it is unlikely this latest warning will have a significant effect on Effexor's sales.
Published By Datamonitor
|
08 Sep 2003 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.